Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical development and manufacturing services provider Althea Technologies has entered into a manufacturing supply deal with a technology based vaccine company Profectus BioSciences.
Subscribe to our email newsletter
Under the deal, Althea will supply gram-scale quantities of current Good Manufacturing Practice (cGMP) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences’ ongoing DNA vaccine development program.
Profectus BioSciences chief scientific officer John Eldridge said the company is pleased to establish partnership with Althea for the production of the clinical grade plasmids for its DNA vaccine programs.
"Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area and we anticipate a long and productive association," Eldridge added.
Althea Technologies president and CEO Rick Hancock said, "By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it."
Profectus’ DNA vaccine development program is supported by a contract from the National Institutes of Health (NIH).